688062 Mabwell
- 32.95
- +0.53+1.63%
Mabwell News
Maiwei Biotech (688062.SH): Net loss of 206 million yuan in the first quarter
Gelonghui, April 29丨Maiwei Biotech (688062.SH) released its report for the first quarter of 2024, achieving operating income of 67.551 million yuan, an increase of 1572.42% over the previous year; net profit attributable to shareholders of listed companies - 206 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 218 million yuan, and basic earnings per share of 0.51 yuan.
With 42% Ownership, Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE:688062) Insiders Have a Lot Riding on the Company's Future
Key Insights Insiders appear to have a vested interest in Mabwell (Shanghai) Bioscience's growth, as seen by their sizeable ownership A total of 6 investors have a majority stake in the company with
Maiwei Biotech (688062.SH) announced its 2023 annual results, with a net loss of 1,053 billion yuan, an increase in losses over the same period last year
Maiwei Biotech (688062.SH) disclosed its 2023 annual report. The company achieved revenue of 128 million during the reporting period...
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment
China's drug regulator approved the marketing application of Mabwell Shanghai Bioscience's (SHA:688062) unit, Jiangsu Taikang Biopharmaceutical, for denosumab, according to a filing with the Shanghai
Maiwei Biotech (688062.SH): Maiweijian was approved for listing by the State Drug Administration
Gelonghui Biotech (688062.SH) announced on April 3, that the marketing application for desulumab injection (9MW0321) submitted by Jiangsu Taikang Biomedical Co., Ltd., a wholly-owned subsidiary of the company, was approved by the National Drug Administration to treat bone giant cell tumors that cannot be surgically removed or may cause serious functional impairment, including adults and young patients with mature skeletal development (defined as at least 1 mature long bone and body weight ≥45 kg). It is the first Agave (desumab injection, 120mg) biosimilar to the marketing of Agave (desumab injection, 120mg), which is approved for marketing in China medicine. My Health is reorganizing the whole team
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Guoxin Securities: Focus on the immediate needs of medical care, focus on the high growth targets of the first quarter report
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE:688062) Shares Could Be 50% Below Their Intrinsic Value Estimate
Key Insights Mabwell (Shanghai) Bioscience's estimated fair value is CN¥61.91 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥31.00 suggests Mabwell (Shanghai) Bioscience is pote
Mabwell Scraps Licensing Deal With Yangtze River Pharma
Mabwell Shanghai Bioscience (SHA:688062) ended a licensing agreement with Yangtze River Pharmaceutical Group for two cancer drugs due to fluctuations in the products' prices. The deal was made through
Maiwei Biotech (688062.SH) Earnings Report: Net loss of $1,053 billion in 2023
On February 23, Ge Longhui Biotech (688062.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 128 million yuan, an increase of 360.49% over the previous year; total profit - 1,056 million yuan; net profit attributable to owners of the parent company - 1,053 million yuan; net profit attributable to owners of the parent company after deducting non-recurring profit and loss - 1,065 million yuan; and basic earnings per share.
Mabwell Shanghai Bioscience Gets US FDA's Nod to Trial on Tumor Drug; Shares Jump 5%
Mabwell Shanghai Bioscience (SHA:688062) will conduct a clinical trial on the 7MW3711 for injection in the US after receiving approval from the country's Food and Drug Administration. The Chinese biop
Maiwei Biotech (688062.SH): New drug clinical trial application for injectable 7MW3711 obtained FDA approval
On February 18, Ge Longhui Biotech (688062.SH) announced that the company received the “Study May Proceed Notification” (Study May Proceed Notification) issued by the US Food and Drug Administration (“FDA”), and the clinical trial application for injectable 7MW3711 for advanced malignant solid tumors was officially approved by the FDA. 7MW3711 is a novel antibody-conjugated drug targeting B7-H3, targeting advanced malignant solid tumors.
Maiwei Biotech (688062.SH): Pre-loss of 956 million yuan to 1.14 billion yuan in 2023
Gelonghui, January 29丨Maiwei Biotech (688062.SH) announced its 2023 annual results forecast. The company expects to achieve net profit attributable to the owner of the parent company in 2023 of -95.60 million yuan to -1140,000 yuan, an increase of 765,400 yuan to 184.7654 million yuan over the previous period, an increase of 0.08% to 19.34% over the previous period. The company is expected to achieve net profit attributable to the owners of the parent company - RMB 96,800 million to RMB 115,200,000 in 2023 after deducting non-recurring profit and loss, compared with
Is Mabwell (Shanghai) Bioscience (SHSE:688062) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
Maiwei Biotech (688062.SH) will list and circulate about 2.873,600 restricted shares starting January 18
Maiwei Biotech (688062.SH) announced that the restricted shares listed in circulation this time are the company's initial public offering strategy...
Maiwei Biotech will attend the 42nd J.P. Morgan Chase Annual Healthcare Conference and deliver a speech at the Biotech Showcase
SHANGHAI, January 2, 2024 /PRNewswire/ -- Maiwei Biotech (688062.SH), an innovative biopharmaceutical company with a full industrial chain, announced that the company's R&D president Dr. Wu Hai will attend the 42nd J.P. Morgan Healthcare Annual Conference held in San Francisco, USA, and delivered a speech at the Biotech Showcase held at the same time on Maiwei Biotech's global cooperation strategy, innovative drug pipelines in the fields of oncology, autoimmunity and central nervous system, and IDDC ADC innovation technology platform. The accompanying R&D and business development team will
Galaxy Securities: Entering a New Era of Targeted Chemotherapy, Focusing on the High Quality Circuit ADC in the Field of Innovative Drugs
According to Galaxy Securities, ADC is a high-quality circuit in the field of innovative drugs. Its targets with high technical barriers and strong platform expandability, leading pipeline progress, and remarkable clinical efficacy are worthy of continuous investment and tracking.
League of Nations Securities: ADC drugs frequently go overseas to cash out products focusing on BIC, FIC, or differentiated advantages
ADC drugs have the potential to replace traditional chemotherapy, and the market space is broad.
Pacific Securities: Domestic ADCs are collectively entering the international market, and the golden age of ADC has just begun
As of December 2023, there have been more than 20 overseas transactions for domestic ADCs, and the transaction amount has exceeded 35 billion US dollars. Once again, Chinese pharmaceutical companies have become the protagonists of innovation.
Maiwei Biotech's application for the launch of a new 8MW0511 drug for injection was accepted by the NMPA
Shanghai, December 15, 2023//PRNewswire/ -- Maiwei Biotech (688062.SH), an innovative biopharmaceutical company with a full industry chain layout, announced that its new drug marketing application for injectable recombinant (yeast-secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein (R&D code: 8MW0511) has been accepted by the National Drug Administration (NMPA) for use by adult non-myeloid malignant cancer patients receiving myelosuppressive cancer anti-drug treatment that is likely to cause febrile neutropenia This product is reduced to heat neutral
Analysis
Price Target
No Data
